Paul Kohlhaas is a prominent serial entrepreneur, economist, and Web3 engineer. He is the Co-Founder and CEO of Molecule, a decentralized biopharma marketplace, and Founding Member of BIO, a biotech DAO and DeSci launchpad. He is working on building a marketplace for drug discovery and development through the use of blockchain technology, enabling IP NFTs and bootstrapping DAOs to invest in them. Paul has spent several years working in the blockchain space—from organizing Ethereum meetups in South Africa to serving as Director of Business Development for ConsenSys. He is also the Co-Initiator of VitaDAO and was the Founder and CEO of Linum Labs, a software development studio focusing on decentralized systems and Web3 applications.
CURRENT AFFILIATIONS
BLOCKCHAIN & BIOTECH EXPERTISE
Paul is a prominent entrepreneur and innovator in the blockchain and biotechnology marketplace.
His work is widely regarded as a disruptive force in the traditional pharmaceutical industry, with the potential to transform how drugs are discovered, funded, and brought to market.
His research centers around the use of token engineering and autonomous market design to design novel incentives and legal structures that drive open source collaboration.
EARLY CAREER
Paul served as Vice President and Advisor for ixo Foundation and Vice Chairman of Advanced Blockchain AG.
He was Director of Business Development at ConsenSys, focused on building the leading digital identity platform, uPort.
He also led uPort's core use cases, including Web2 and Web3 applications for dApps and enterprises across US, Europe and Asia.
He was the Founder and CEO of Linum Labs, where they developed in-house solutions from security audits to bespoke development and smart contract architectures.
Paul was a Meetup Organizer for Ethereum and a Business Development Lead for Trustlab Blockchain Innovation Studio.
He started his career as an Investment Analyst for Sovereignty Capital.
MEDIA & APPEARANCES
Paul is a thought leader in both the blockchain and biotech spaces, frequently speaking at conferences.
He has appeared as a guest on Real Vision.